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Abstract 
Frutalin is the α-D-galactose-binding jacalin-related lectin isolated from breadfruit seeds 
(Artocarpus incisa). Frutalin has been previously produced in Pichia pastoris and in Escherichia coli in 
order to overcome the limitations associated with the extraction from its natural source. A previous study 
also showed that recombinant frutalin expressed in Pichia pastoris and purified by size-exclusion 
chromatography (SEC) induces apoptosis in HeLa tumoral cells. Nevertheless, the molecular mechanism 
of apoptosis induction triggered by frutalin has not been studied.  
Therefore, with the present work it was intended to elucidate the molecular mechanism involved in 
apoptosis induction by the recombinant frutalin expressed in Pichia pastoris and purified by SEC. To 
achieve such a goal, the modulatory effect of frutalin on main regulatory proteins of apoptosis, such as the 
executioner members of the caspase family (caspases-3, -6 and -7) and the p53 family members was 
studied using yeast-based assays. The results obtained showed that the p53 family proteins (p53, p63, 
p73 and DN) are not direct targets of frutalin. Moreover, using human tumor cells with (HCT116 p53+/+) 
and without (HCT116 p53-/-) wild-type p53, we confirmed that frutalin induces apoptosis by a p53-
independent pathway. Concerning the procaspases-3, -6 and -7, the results obtained suggest that frutalin 
induces apoptosis by a caspase-dependent pathway.  
In addition, different molecules of frutalin expressed in a different expression system (E. coli) 
and/or purified by a different methodology (hydrophobic interaction chromatography; HIC) were tested for 
its anti-proliferative activity in order to see if one could improve the production and purification process. 
Thus, the activity of frutalin produced in the bacteria Escherichia coli and in the yeast Pichia pastoris 
purified by HIC was also evaluated regarding its effect on the proliferation of HCT116 p53+/+ tumor cells. 
The frutalin expressed in E. coli did not inhibit cell proliferation. Additionally, frutalin expressed in              
P. pastoris and purified by HIC, resulted in two different samples suggesting that one is partially 
glycosylated and the other is non-glycosylated. The sample partially glycosylated also showed an inhibitory 
of proliferation of HCT116 p53+/+ tumor cells. However, this activity was less potent than the one obtained 
with frutalin from P. pastoris and purified by SEC. The sample non-glycosylated had no anti-proliferative 
effects. The same result was obtained for frutalin expressed in E. coli, suggesting that glycosylation affects 
the biological activity of frutalin. 
In conclusion, trials to obtain the recombinant frutalin in a more straightforward 
production/purification process were ineffective as alternative systems, because the anti-proliferative 
activity of frutalin was compromised. Frutalin produced from Pichia pastoris and purified by SEC has, 
nevertheless, a potent anti-proliferative effect on HCT116 tumor cells and induces apoptosis through a 
caspase-dependent pathway. 
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Resumo 
Frutalina é uma lectina α-D-galactose-ligante jacalina-relacionada isolada nas sementes da planta 
fruta-pão (Artocarpus incisa). A frutalina foi produzida, anteriormente, em Pichia pastoris e em Escherichia 
coli de modo a superar limitações associadas à sua extração da fonte natural. Um estudo anterior mostrou 
que a frutalina expressa em Pichia pastoris e purificada por cromatografia de exclusão de peso molecular 
(SEC) induz a apoptose em células tumorais humanas. Todavia, o mecanismo molecular de indução da 
apoptose pela frutalina ainda não foi estudado.  
Assim, com o presente trabalho pretende-se elucidar o mecanismo molecular envolvido na 
indução da apoptose pela frutalina expressa em P. pastoris e purificada por SEC. Para atingir este objetivo 
foi estudado, através da utilização de um modelo celular de levedura, o efeito modulador da frutalina nas 
principais proteínas reguladoras da apoptose como membros da família de caspases executoras 
(caspases-3, -6 and -7) e membros da família da proteína p53 (p53, p63, p73 e DN). Os resultados 
obtidos mostraram que os membros da família da proteína p53 não são alvos diretos da frutalina. Além 
disso confirmou-se, através da utilização de células tumorais humanas com (HCT116 p53+/+) e sem 
(HCT116 p53-/-) a forma nativa da p53, que a frutalina induz a apoptose por uma via independente da 
p53. Relativamente aos resultados obtidos para as procaspases-3, -6 e -7, estes sugerem que a frutalina 
induz a apoptose por uma via dependente das caspases.  
Foi testada, também, a atividade anti-proliferativa de diferentes moléculas de frutalina expressa 
num sistema de expressão diferente (E. coli) e/ou purificada por uma metodologia diferente 
(cromatografia de interação hidrofóbica; HIC), a fim de se verificar se poderiam melhorar o processo de 
produção e purificação. Assim, foi avaliado o efeito da frutalina produzida na bactéria Escherichia coli e na 
levedura Pichia pastoris purificada por HIC na proliferação de células tumorais HCT116 p53+/+. A frutalina 
expressa em E. coli não inibiu a proliferação celular. Adicionalmente, a frutalina expressa em Pichia 
pastoris e purificada por HIC resultou em duas amostras diferentes sugerindo que uma é parcialmente 
glicosilada e outra não é glicosilada. A amostra parcialmente glicosilada mostrou ter efeito na inibição da 
proliferação das células tumorais HCT116 p53+/+. No entanto, esta atividade é menos potente do que a 
obtida com a frutalina expressa em P. pastoris e purificada por SEC. A amostra não glicosilada não teve 
efeito na inibição da proliferação celular. O mesmo resultado foi obtido para a frutalina expressa em E. coli 
sugerindo que a glicosilação afeta a atividade biológica da frutalina.   
Em conclusão, os ensaios para obter a frutalina recombinante através de um processo de 
produção/purificação mais simples foram ineficazes como sistemas alternativos, uma vez que 
comprometeram a atividade anti-proliferativa da frutalina. A frutalina produzida por Pichia pastoris e 
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purificada por cromatografia de exclusão de peso molecular tem, no entanto, um potente efeito anti-
proliferativo nas células tumorais HCT116 e induz a apoptose por uma via dependente das caspases.  
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1.1 Plant lectins 
Lectins are a heterogeneous group of proteins with at least one non-catalytic domain that 
selectively recognizes, and reversibly binds to, specific free sugars or glycans present on glycoproteins and 
glycolipids without altering the structure of the carbohydrates [1]. These are distributed in nature namely in 
plants, viruses, animals, bacteria, vertebrates and invertebrates [1, 2]. The first description of plant lectins 
dates back to the late nineteenth century when Peter Stillmark initiated the study of proteins derived from 
plants that have demonstrated the ability to agglutinate erythrocytes [3, 4]. In 1988, in his doctoral thesis, 
he described the properties of agglutination of proteins that had been extracted and partially purified from 
castor seeds (Ricinus communis) denominated ricin. Table 1 describes the main events, over time, in 
relation to plant lectins.  
Table 1. Major historic events of plant lectins (adapted from [5]) 
Year Description  
1888 
Detection of erythrocyte agglutination by a toxic protein fraction from castor seeds (termed ricin) (P. 
Stillmark) 
1891 Toxic plant agglutinins applied as model antigens (P. Ehrlich) 
1898 
Introduction of the term “haemagglutinin” or “phytohaemagglutinin” for plant proteins that 
agglutinate red blood cells (M. Elfstrand) 
1907/1909 
Detection of non-toxic agglutinins in plants, of their nature as proteins and of “deagglutination” of 
erythrocytes by hog gastric mucin (K. Landsteiner, H. Raubitschek) 
1919 Crystallization of a globulin from jack bean, concanavalin A  (J. B. Sumner) 
1935/1936 Concanavalin A identified as jack bean haemagglutinin (J. B. Sumner) 
1947/1948 
Detection of plant agglutinins specific for the human histo-blood group A (W. C. Boyd; K. O. 
Renkonen) 
1952 
Use of lectins and glycosidases to prove that blood group antigens are sugars and to deduce the 
structures of the antigens (W. M. Watkins, W. T. J. Morgan) 
1954 Introduction of the term “lectin” for plant agglutinins (W. C. Boyd) 
1960 Detection of the mitogenic potency of lectins toward lymphocytes (P. C. Nowell) 
1963 Introduction of affinity chromatography for the isolation of lectins (I. J. Goldstein, B. B. L. Agrawal) 
1972 
Determination of the amino acid sequence and the three-dimensional structure of a lectin, 
concanavalin A (G. M. Edelman, K. O. Hardman, C. F. Ainsworth et al.) 
1983 Detection of the insecticidal action of a plant lectin (L. L. Murdock) 
1984 Isolation of lectins from tumors (H.-J. Gabius; R. Lotan, A. Raz) 
1989 Detection of the fungicidal action of a plant lectin (W. J. Peumans) 
1995 
Structural analysis of a lectin-ligand complex in solution by NMR spectroscopy (J. Barbero and 
colleagues) 
2001-2005 
Development of glycan/lectin microarrays for specificity analysis of lectins/ structural analysis of 
glycans and glycoproteomics  (various laboratories worldwide) 
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The proteins that have ability to agglutinate other cells began to be called agglutinin and 
phytohemagglutinins [4, 6]. Later, in 1954, Boyd proposed the name lectin (derived from the Latin 
“legere”, which means "to select", "who chooses") due to its ability to agglutinate erythrocytes [2, 3, 5]. 
Although nowadays the term lectins is the most commonly used, the term hemagglutinins and agglutinins 
can also be used to denominate them. This denomination is considered by some authors as the most 
accurate, since it refers to the ability of the proteins to agglutinate erythrocytes and other cell types [3, 4].  
Lectins were initially defined as a group of “carbohydrate-binding proteins of non-immune origin 
that agglutinate cells and/or precipitate glycoconjugates”. This definition has been accepted, albeit with 
limitations, by the Nomenclature Committee of the International Union of Biochemistry [4]. One limitation 
of this definition is that excludes many lectins. This is because this definition only refers to multivalent 
carbohydrate-binding proteins excluding proteins which have a single carbohydrate-binding domain, which, 
do not have the ability to agglutinate cells or precipitate glycoconjugates [4]. In 1995, Peumans and Van 
Damme proposed a new definition for lectins: “all plant proteins that possess at least one noncatalytic 
domain that binds reversibly to a specific mono- or oligosaccharide” [3]. The definition that has been 
considered the most appropriated is that lectins are heterogeneous group of proteins with at least one non-
catalytic domain that selectively recognizes, and reversibly binds to, specific free sugars or glycans present 
on glycoproteins and glycolipids without altering the structure of the carbohydrates [1].  
Thereafter it was proposed a subdivision of lectins on “merolectins”, “hololectins”, 
“chimerolectins” and “superlectins” (Figure 1) according to the overall structure of the mature lectins [4].   
 
 
Figure 1. Schematic representation of merolectin, hololectin, chimerolectin and superlectin (adapted from [4]). 
Merolectins only have a single domain binding to carbohydrates. Therefore, they are unable to 
agglutinate cells and precipitate glycoconjugates. Hololectins have two or more carbohydrate-binding 
domain wherein at least two of the binding domains are identical or homologs and bind to the same sugar 
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or with a similar structure. Hololectins are di- or multivalent and unlike merolectins have the ability to 
agglutinate cells and/or precipitated glycoconjugates. Chimerolectins exhibit one or more carbohydrate 
binding domain(s) tandemly arrayed to an independent domain that can have a well-defined enzyme 
activity or other biological activity. This activity should be independent of carbohydrate binding domains, 
and the number of these domains determines the behavior of these lectins. Thus, if they only have one 
binding domain, they behave as merolectins, whereas when they have more than one domain they behave 
as hololectins. Finally, superlectins are formed as hololectins with at least two carbohydrate binding 
domains. However, unlike hololectins these domains are structurally and functionally different, and can 
recognize different sugars structures [3, 4].  
Lectins widely differ from each other relatively to their biochemical/physicochemical properties, 
affinity for carbohydrate, molecular structure and biological activities [3]. Thus, Peumans and Van Damme 
[3] classified lectins into seven distinct families in accordance with the molecular structure and specificity 
of the carbohydrate. Therefore, lectins of a given family share common features between them. Within the 
seven families of lectins, four are numerous, including the legume lectins, the monocot mannose-binding 
lectins, the chitin-binding lectins, and the type 2 ribosome-inactivating proteins (RIPs). The jacalin-related 
lectins, the amaranthin lectin family and the Cucurbitaceae phloem lectins are considered small families 
[4]. Lastly, plant lectins have been divided into twelve different families based on carbohydrate binding 
domain (e.g. jacalins, proteins with legume lectins domains and ricin-B family) and according to molecular 
structures and amino-acid sequences [1].  
1.1.1 Potential biomedical applications of plant lectins 
As mentioned before, most lectins have the ability to agglutinate other cells. This effect is directly 
related to their ability to recognize and to bind reversibly to specific sugar structures, establishing a 
connection protein-carbohydrate. This feature allows lectins mediate a variety of biological processes, such 
as cell-cell communication, differentiation and cancer metastasis, as well as innate immune responses [1, 
2].  
Lectins are used as research tools in many scientific areas, namely in biochemistry, immunology, 
cell biology and even in the diagnosis and treatment of cancer [7]. 
The use of lectins in the diagnosis and treatment of cancer, a major disease of the XXI century, 
has contributed to the growing interest in the study of these proteins [8]. Lectins have contributed to the 
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recognition of surface markers, mitogenic stimulation, cell adhesion and localization, increase of host 
immune defense, cytotoxicity and apoptosis [9–11]. 
Several studies have indicated that cancer cells have an aberrant glycosylation [12]. Once lectins 
bind to specific carbohydrates, they can be used to detect aberrant glycosylation. One study showed that 
the lectins Concanavalin A (Con A) and Ulex europeus I (UEA-I) can be used as histochemical biomarkers 
of mucoepidermoid carcinoma (MEC) in the most common malignant salivary tumor, which can be 
classified as low, intermediate or high grade. Con A binds to the neoplastic cells of the three degrees of 
severity. UEA-I is connected more strongly to cells of intermediate grade and more weakly to the other 
degrees [13].  
Some lectins have showed the ability to induce cell recruitment, lymphocyte proliferation, and 
cytokine production and to possess immunomodulatory activity. Lectins (KML-C) from Korean mistletoe 
(Viscum album coloratum) showed differentially modulated macrophage-mediated immune responses. 
Moreover, they increased expression of various cytokines (IL-3, IL-23 and TNF-a) and reactive oxygen 
species (ROS) production [14]. 
1.1.2 Jacalin-related lectins (JRLs) 
Jacalin-related lectins are considered a small family, when compared with other existing families of 
lectins. JRLs are divided into two subfamilies according to their specificity to carbohydrate. This family is 
subdivided into lectins which have an affinity to bind to the galactose (gJRLs) and mannose/maltose 
(mJRLs) [4, 15]. The “galactose-specific” and “mannose-specific” jacalin-related lectins beyond the 
differences on the specificity to carbohydrate, they also differ in their biosynthesis, processing, topogenesis 
and intracellular location [16]. 
Concerning to the biosynthesis differences between gJRLs and mJRLs, in the case of gJRLs it 
undergo proteolytic cleavage of the precursor polypeptide, resulting in two polypeptide chains, a heavy 
chain (α) and a light chain (β) of 133 and 20 amino acids, respectively [4, 15, 16]. Comparatively, the 
mJRLs does not undergo proteolytic modification, consisting only by uncleaved protomers with 
approximately 150 amino acids [15, 16]. 
There are evidence that the mannose-specific jacalin-related proteins are located in the cytoplasm, 
where they are synthesized [16]. These are not subject to any post-translational modifications and the 
mature polypeptides of the mJRLs correspond to the entire open reading frame of their corresponding 
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genes [4, 16]. As a cleavage of protomer has not been found, the mJRLs have an extra loop, which makes 
the binding site inaccessible to galactose [17]. 
Jacalin, a “galactose-specific” jacalin-related lectin is synthesized in the endoplasmic reticulum 
[16] as preprojacalin consisting of a signal peptide of 21 amino acid residues followed by a propeptide of 
39 amino acid residues, aβ chain with 20 amino acid residues, a linker tetrapeptide (TSSN), and lastly, a
α chain with 133 amino acid residues. Its co-translational processing involves the removal of a signal 
peptide and its partial glycosylation, given rise to the propeptide that is transported to the Golgi complex 
(Figure 2) [4, 16, 17]. Subsequently, the propeptide is cleaved at three different locations, with the removal 
of the N-terminal propeptide and of the linker tetrapeptide. Thus, the mature jacalin is constituted by ta N-
terminalβchain and a C-terminalαchain with 20 and 133 amino acid residues, respectively, being 
located in the vacuole. It is possible that its processing be similar to other jacalin lectins from Artocarpus 
plant, as well as from plant Maclura pomifera [4, 16].  
 
 
Figure 2. Schematic representation of molecular structure, biosynthesis and processing of “galactose-specific” 
jacalin-related lectins (adapted from [4]).  
 
1.2 The frutalin lectin 
Frutalin is a lectin isolated from the seeds of the Artocarpus incisa plant, commonly known as 
breadfruit. This plant belongs to the Moracae family, and it can be found in areas with a humid tropical 
climate. In Brazil, it is possible to find two different types of this plant, the apyrena (non-seminífera), 
without seeds, and the one that has seeds (seminífera) [18]. 
The frutalin is a tetrameric partially N-glycosylated protein which specifically recognizes α-D -
galactose residues [18]. It belongs to the jacalin-related lectins family, specifically to the subfamily 
“galactose-specific” jacalin-related lectins. Frutalin has many structural and functional similarities with 
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jacalin, found in Artocarpus integrifolia plant that belongs to the same family as Artocarpus Incisa, Moracae 
family [18, 19]. As previously described, frutalin is a tetrameric molecule of approximately 48-49 kDa, 
consisting of four monomers linked by non-covalent bonds. Each monomer consists on a heavy chain (α) 
of 133 amino acids non-covalently bound to a light chain (β) of 20 amino acids. Frutalin presents 
predominantly a β sheet conformation and contains four binding sites for D-galactose, being therefore 
considered, according to its structure, a "hololectin" [17, 18, 20].  
Immunologic studies showed that frutalin is a potent mitogenic activator of human lymphocytes 
and it has the ability to induce in vivo and in vitro neutrophil migration [19, 21]. 
1.3 Heterologous expression of frutalin 
The use of recombinant lectins as potential therapeutic and diagnostic agents makes important to 
reduce the heterogeneity of properties resulting from the different lectins isolated from natural sources. In 
fact, lectins may have different isoforms that can lead to different specificities to carbohydrates. The 
heterologous expression and production of recombinant proteins reveals to be an important to overcome 
the limitations mentioned above. Additionally, the purification of lectins from its natural source can be a 
time-consuming process and with a low yield. This is also other limitation that can be overcome by the 
expression and production of these recombinant proteins. Additionally, through the heterologous 
expression and production of lectins is possible to obtain larger amounts of lectins with high levels of purity 
and with defined amino acid sequence, in a shorter period of time, when compared to the native lectins 
system. Therefore the properties of lectins are also more controlled [1, 22].  Thus, the use of heterologous 
expression systems have considerable advantages for the production of proteins of pharmaceutical interest 
[23], particularly for the study of cellular processes [24]. 
1.3.1 Pichia pastoris and E. coli as expression system 
The ideal system should be able to express proteins with the lowest possible cost and as authentic 
as possible [25]. The expression system using bacterium E. coli and the yeast P. pastoris are, currently, 
the two most used expression systems [26, 27]. 
Initially, E. coli was the most used production system, due to extensive knowledge on its genetics, 
easy of manipulation, low generation time and high product yields [23, 28]. However, have significant 
limitations to the expression of recombinant protein using E. coli as an expression host. E. coli is unable to 
perform the post-translational modifications such as glycosylation or disulfide bond formation. These 
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modifications can affect the bioactivity, function, structure, solubility, stability, half-life, protease resistance, 
and compartmentalization of the functional proteins [27]. Despite of this, many proteins (e.g. IFN -α, -β 
and -γ, interleukin-2) that are non-glycosylated after expression in E. coli (glycosylated in their natural 
human forms) retain their biological activity. Another disadvantage of E. coli as an expression system is 
that most of proteins are produced in inclusion bodies and are often inactive, insoluble and require 
refolding [26].  
New strategies have been developed in order to overcome some limitations, such as the solubility 
of the proteins expressed in E. coli. One example of a reliant strategy was the fusion proteins technology. 
Fusion partners (e.g. Fh8 tag), when fused with the protein of interest, can increase production yields, 
protein solubility and can be used (e.g. His tag) in the purification process [27, 29]. These limitations, in 
association with the high number and complexity of recombinant proteins to be expressed, led to the use 
of other hosts besides the E. coli in heterologous expression systems. Although the limitations exposed 
above E. coli remains one of the preferred hosts (host for recombinant protein expression) [30].   
Pichia pastoris, the methylotrophic yeast, can overcome some of the limitations presented by the 
E. coli expression system. It is capable of post-translational modifications, namely to carry out proteins 
glycosylation’s and to produce disulfide bonds [26]. These are major advantages of the P. pastoris over 
E.coli. Furthermore, production yields can be higher than E. coli. However, it may be necessary to optimize 
the growth conditions [26, 27]. Another advantage of the methylotrophic P. pastoris when compared to 
other organisms including E. coli, is its ability to secrete proteins efficiently. In spite of this, as a host for 
heterologous expression, Pichia pastoris also present some disadvantages. For example, P. pastoris can 
not produce proteins that require the assistance of folding chaperones. [26]. Table 2 describes the main 
advantages and disadvantages of the heterologous expression system E. coli and P. pastoris. 
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Table 2. Advantages and disadvantages of E. coli and P. pastoris expression systems (adapted from [1]) 
Host system Advantages Disadvantages 
E. coli Rapid expression 
High yields 
Genetically manipulate 
Inexpensive 
Mass production fast and cost-effective 
Proteins with disulfide bonds difficult to 
express  
Produce unglycosylated proteins 
Proteins produced with endotoxins 
Proteins produced as inclusion bodies, 
are inactive and usually require refolding. 
P. pastoris High yield 
Stable production strains 
Durability 
Cost effective 
High density growth 
High productivity 
Stability proteins  
Rapid growth in chemically defined 
media 
Product processing similar to 
mammalian cells 
Can handle S–S rich proteins, assist 
protein folding and glycosylate proteins 
Fermentation require for very high yield 
Growth conditions may require 
optimization 
Refolding may be required 
 
1.3.2  Recombinant frutalin 
Recombinant frutalin was expressed in a recombinant form in yeast Pichia pastoris and in bacteria 
Escherichia coli [29, 31, 32]. However, recombinant frutalin expressed in P. pastoris and E. coli exhibits 
differences between them.  One major difference between them is the glycosylation. The frutalin expressed 
in Pichia pastoris is partially N-glycosylated whereas the frutalin expressed in E. coli is non-glycosylated.  
Furthermore, frutalin in E. coli showed ability to agglutinate rabbit erythrocytes contrary to frutalin in P. 
pastoris that did not showed this ability [31, 32].  
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Additionally, differences between recombinant and native frutalin can also be found. In fact, during 
the processing in P. pastoris and in E.coli, the cleavage of linker tetrapeptide (T-S-S-N) does not occur in 
recombinant frutalin. Therefore, in recombinant frutalin, the α and β chains are not independent, being 
expressed as a single chain protein. Although the differences between recombinant and native frutalin, the 
ability to bind to Me-α–galactose was retained by the recombinant frutalin but with lesser affinity than 
native frutalin [31, 32].  
Recombinant frutalin expressed in E. coli was mainly produced as insoluble protein [32] and in 
order to increase the amount of frutalin, a fusion partners was used to increase production yields, promote 
its solubility and help on its purification. The fusion of frutalin with the Fh8 tag resulted in an increase of 
soluble expression and His6 tag was used for help on its purification [29, 32].  
1.3.3 Potential biomedical applications of recombinant frutalin  
Oliveira et al. [12, 33] demonstrated the potentiality of recombinant frutalin expressed in P. 
pastoris as agent for the treatment and diagnosis of cancer. 
Several studies showed that lectins have a promising capacity as tumor biomarkers. Recently, 
through immunohistochemical assays, frutalin was tested in human tissues of prostate carcinoma and 
benign prostate hyperplasia (BPH) as potential tumor biomarker. This study compared if native frutalin 
(from Artocarpus incisa) and recombinant frutalin were able to detect alterations in human prostate 
tissues. The native frutalin (n-frutalin) bound to all cases studied of prostate carcinoma and to benign 
prostate hyperplasia (BPH), 20 and 25 cases, respectively. Regarding to recombinant frutalin (r-frutalin), it 
bound to 14 of the 20 studied cases of prostate carcinoma and did not bind to none of the 25 studied 
cases of BPH. Recombinant frutalin showed that recognize specifically malignant cells. These differences 
can be due to distinct carbohydrate binding affinity. Thus, Oliveira et al. [12] concluded that native and 
recombinant frutalin could be used as histochemical biomarkers for the prostate cancer.  
In another study by Oliveira et al. [33], it was found a cytotoxic effect of frutalin (native and 
recombinant) in HeLa cervical cancer cells (Figure 3). In fact, recombinant and native frutalin had similar 
effects in inhibiting the proliferation of HeLa cells (GI50 for 24 h ≈ 100 µg/mL), an effect that showed to be 
time- and dose-dependent.  
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Figure 3. Effect of different concentrations of n- frutalin and r- frutalin on HeLa cells proliferation at 24 and 48 h 
[33]. 
This same study showed that the inhibition of proliferation occur due to apoptotic cell death. It was 
also analysed the cellular localization of each lectin studied. Interestingly, it was found that the 
recombinant frutalin was mainly located in the nucleus, whereas native frutalin was mainly located in the 
perinuclear region. This study therefore revealed a potential therapeutic application of native and 
recombinant frutalin against cancer [33].  
1.4 Plant lectin-induced apoptosis 
Apoptosis is a programmed cell death process, involved in the control of cellular proliferation and 
DNA damage [11]. This is characterized by typical morphological cell changes like nuclear fragmentation, 
chromosomal fragmentation, membrane blebbing and nuclear condensation [24, 34].  
Apoptosis can be induced through several molecular pathways. The extrinsic and intrinsic pathways 
are the most relevant pathways in apoptosis [35]. The induction of these two apoptotic signaling pathways 
leads to the activation of the executioner caspases that results in the cleavage of a subset of proteins 
resulting in the biochemical and cellular changes typical of apoptosis [36, 37]. Caspases are a family of 
cysteine- dependent aspartate-specific proteases that can be divided in pro-apoptotic and pro-inflammatory 
subfamilies. The pro-apoptotic subfamily can be divided in activator or initiator caspases (caspase-2, -8, -9, 
-10 and -12) and executioner or effector caspases (caspase-3, -6 and -7) that are activated by the initiator 
caspases. These are synthetized as inactive preforms and stored as procaspases that under certain 
conditions are activated by proteolysis and become able to cleave a large set of substrates [38, 39].  
The extrinsic pathway (or the death receptor pathway) involves the activation of receptors in plasma 
membrane by binding of ligands. These receptors are known as death receptors (DR), such as Fas and 
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KILLER/DR5. The activation of receptors through binding of specific ligand leads to their trimerization and 
consequent clustering of the intracellular death domain that results in recruitment of FAS associated with a 
death domain (FADD), which in turn recruits caspase-8 allowing the formation of the death-inducing-
signaling-complex (DISC) [36, 37]. 
The intrinsic pathway (or mitochondrial pathway) involves the mitochondrial outer membrane 
permeabilization (MOMP), which allows a release to cytosol of pro-apoptotic proteins such as cytochrome C 
(cyt c) and apoptosis-inducing factor (AIF). The cytochrome c plays an important role in mitochondria-
dependent apoptotic death. Upon its release it combines to the apoptosis protease-activating factor 1 
(APAF-1) and the initiator caspase-9 inducing the formation of a large complex, the apoptosome, which 
promotes the proteolytic maturation of caspase-9. With active caspase-9, the effector caspases (caspase-3, 
-6 and -7) are cleaved and activated, which in turn leads to the apoptosis [36, 37].  
The p53 family protein, has an important role in induction of apoptosis, namely in the intrinsic and 
extrinsic pathway. The p53 family protein may up-regulate several proteins involved in the intrinsic 
pathway. The Bcl-2 family of proteins are involved in the release of cytochrome c from the mitochondria 
[35]. The pro-apoptotic proteins from Bcl-2 family (e.g. Bax, Bid, Noxa, Puma) may up-regulate by p53 that 
results in MOMP, which in turn activate caspases leading to apoptosis [24, 36, 37]. The p53 and p73 
induce the expression of p53AIP1 (p53-apoptosis inducing protein 1), which localizes to the mitochondria 
where it interacts with Bcl-2 to facilitate the release of cyt c and the consequent apoptosis induction 
through the intrinsic pathway. The p53 can also directly induce the expression of caspase-6 and Apaf-1. 
The p53 can upregulating two cell death receptors, KILLER/DR5 and Fas and the ligand for Fas, FasL and 
thus, induce the apoptosis through extrinsic pathway [35, 40]. 
Some of the proteins mentioned above that are involved in apoptosis such as initiator or effector 
caspases and p53 are lost in many cancers by inactivation or mutation of these proteins [41]. As such, 
induction of apoptosis by activation of these proteins is a defense against cancer and therefore an 
important target for cancer therapy [42–44]. Moreover, it is an important cellular homeostasis mechanism 
that ensures the correct development and function of multicellular organisms [45].  
Different lectins induce apoptosis in different human tumor cells. The effects of plant lectins in 
human tumor cells are dependent of the sort of lectin and cells lineage. Their effect is time-dosage 
dependent. For example, Polygonatum odoratum lectin (POL), a mannose-binding lectin induces apoptosis 
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through the death-receptor apoptotic pathway by increasing the levels of FasL and Fas-Associated protein 
with death domain (FADD) proteins that leads to the caspase -8 activation. Moreover, POL treatment leads 
to cytochrome c release and subsequent activations of caspase -9 and caspase -3. Thus, POL induces 
apoptosis in a caspase-dependent manner [46]. Polygonatum cyrtonema lectin (PCL), a mannose/sialic 
acid-binding lectin induces, simultaneously, apoptosis and autophagy in human melanoma A375 cells. 
PCL binds to the mannose-containing receptor of human melanoma cell surface and it is internalized and 
localized on the mitochondria. PCL induced mitochondria to generate massive ROS production promotes 
the release of cytochrome c and activates the p38 and p53. Thus, PCL induces apoptosis via a 
mitochondrial ROS-p38-p53 pathway [47]. SFL, a mannose-binding lectin from Sophora flavescens, was 
also shown to induce apoptosis in human cervical cancer in a typical caspase-dependent manner by death 
receptor pathway [42]. Likewise, the lectin ricin induces apoptosis through activation of caspase-8 and 
subsequent activation of caspase -3 and -7 [48]. The Figure 4 demonstrates the plant lectin-induced 
apoptotic mechanisms implicated in intrinsic and extrinsic pathways.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Plant lectin-induced apoptosis was mainly mediated by intrinsic pathway (or mitochondrial pathway) 
and/or extrinsic pathway (or the death receptor pathway) [46]. 
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1.5 Saccharomyces cerevisiae as a model organism for molecular and 
pharmacological studies of human proteins 
Model organisms have widely contributed to the knowledge of human cellular processes and 
proteins [24].  
In fact, the use of Saccharomyces cerevisiae as a model organism has greatly contributed to the 
study of fields as diverse as cell metabolism, DNA replication, recombination, cell cycle, cell death, protein 
folding, trafficking, and organelle biogenesis [24]. S. cerevisiae was the first eukaryote to have its genome 
fully sequenced [49]. These data are easily accessible on the online dataset for yeast with genetic 
interactions, transcriptional changes, protein interactions, and localization information [24, 50, 51]. 
Additionally, it can be easily genetically manipulated, and there is a lot of information about their molecular 
biology and physiology. Another advantage of this yeast as a model organism is its short generation time, 
widely easy to cultivate and maintain [23]. 
Several cellular processes present in S. cerevisiae, such as cell cycle progression, protein secretion 
and apoptosis, are similar to those present in humans, thus allowing the understanding of the biological 
mechanism involved in human diseases. In fact, many of knowledge obtained from yeast has been 
transposed to the human cells [49, 52]. 
To establish these models for the study of heterologous proteins different approaches can be used. 
If the gene encoding the human protein is conserved in yeast, it is possible to study directly the function of 
the protein in this organism. However, if yeast does not possess orthologous of the human gene, it is 
necessary its heterologous expression in this organism (called "humanized yeast").  The heterologous 
expression in yeast of proteins involved in human diseases, has provided important information regarding 
the functions of these proteins (e.g. p53 and caspase family members) and about the pathobiology 
underlying human diseases, such as cancer [24]. 
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1.6 Aims of the work 
In a previous study, recombinant frutalin expressed in Pichia pastoris and purified by size-exclusion 
chromatography showed a strong anti-proliferative effect on HeLa cervical tumor cells. Moreover, it was 
shown that this effect was due to the induction of cell dead by apoptosis. However, the molecular 
mechanism involved in apoptosis induction triggered by this recombinant frutalin was not studied.  
Thus, the main goal of this work was to elucidate the molecular mechanism involved in apoptosis 
induction by the recombinant frutalin expressed in Pichia pastoris and purified by size-exclusion 
chromatography.  
Furthermore, it was also aim of this work to test other frutalin molecules obtained with another 
expression system (Escherichia coli) or/and another purification methodology (hydrophobic interaction 
chromatography). These other recombinant forms of frutalin were produced with a more straightforward 
production and purification process but their anti-proliferative activity in human tumor cell lines was never 
tested before.  
Based on this, the specific aims of this work were to: 
• Study the modulatory effect of frutalin expressed in P. pastoris and purified by size-exclusion 
chromatography on main regulatory proteins of apoptosis, such as the executioner members 
of the caspase family (caspases-3, -6 and -7) and the p53 family members using yeast- based 
assays;  
• Study the effect of frutalin expressed in P. pastoris and purified by hydrophobic interaction 
chromatography in the proliferation of human tumor cell lines;  
• Study the effect of recombinant frutalin obtained from E. coli and purified using affinity 
chromatography with nickel in the proliferation of human tumor cell lines. 
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2.1 Systems of production and purification of recombinant proteins 
2.1.1 Production of recombinant frutalin expressed in Pichia pastoris 
Pichia pastoris KM71H/ pPICZα/ frutalin cells [31], were grown in 100 mL of buffered minimal 
glycerol medium (BMG) with 1% glycerol (AppliChem), 100 mM potassium phosphate (pH 6.0; 
AppliChem), 1.34% yeast nitrogen base with ammonium sulfate and without amino acids (Difco) and 4 × 
10 -5 biotin (Sigma), overnight, at 30 °C, with continuous shaking (200 rpm). The next day, cells were 
harvested by centrifugation at 4000 g for 10 minutes at room temperature and the resulting cell pellets 
were resuspended in 50 mL of fresh buffered minimal methanol medium (BMM). BMM medium has the 
same composition of BMG medium but glycerol is replaced with 0.5% (w/v) methanol (Biochemicals). The 
induction of cultures was carried out in 500 mL baffled shake flask and covered with two layers of sterile 
gauze. Inducible cultures were incubated at 15 °C, with continuous shaking (200 rpm) and fresh methanol 
was added daily, during the 4 days of induction, to a final concentration of 0.5% (v/v). After the induction 
period, the supernatants were separated from cell pellets by centrifugation at 4000 g, 4 °C for 10 
minutes. To precipitate salts, the pH of the supernatants was increased to 7.5 by adding 10 N NaOH and 
removed by centrifugation twice at 4000 g, 10 minutes at 4 °C. 
2.1.2 Purification of recombinant frutalin expressed in Pichia pastoris 
The supernatants were filtered through filters of 0.2 µm, concentrated and washed with Phosphate 
Buffered Saline (PBS; 137 mM NaCl, 2.7 mM KCl, 2 mM KH2PO4, 100 mM Na2HPO4) in 10 kDa Amicon 
filters (Millipore) to a final volume of 1–1.5 mL. To confirm the presence of recombinant frutalin in the 
samples, these were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
and stained with Coomassie (described in section 2.1.5/2.1.5.1). After this, samples were purified by size-
exclusion chromatography (SEC) or hydrophobic interaction chromatography (HIC). At the end of 
purification, samples were quantified by absorbance 280 nm, using NanoDrop 1000 (Thermo Scientific) 
based on molar extinction coefficient of frutalin (εfrutalin = 27390 M-1 cm-1).  
2.1.2.1 Size-exclusion chromatography (SEC) 
SEC is a chromatography technique that separates biomolecules according to differences in their 
size. In this work, a SephacrylTM S-200 HR column (GE Healthcare) was used in FPLC system (Pharmacia 
Biotechnology). In the first step, the column was equilibrated with PBS at a flow rate of 1 mL/min. The 
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sample was filtered through 0.2 µm pore size filters and applied on the column at a flow rate of 1 mL/ min 
and elution occurs under the same conditions. Purified samples were collected and aliquot to be analyzed 
by SDS-PAGE (described in section 2.1.5/2.1.5.1). The samples containing pure recombinant frutalin were 
concentrated in 10 kDa Amicon filters (Millipore) and then stored at –20 °C. 
2.1.2.2  Hydrophobic interaction chromatography (HIC)  
HIC separates biomolecules according to the differences in their hydrophobicity. In this work, a 
prepacked Phenyl SepharoseTM 6 fast flow High Sub column (GE Healthcare) was used operated by a 
peristaltic pump (Pharmacia LKB pump) and the whole procedure of purification was performed at 4 °C. 
Table 3 presents the description of buffers used in this purification in order to optimize the elution 
conditions. In the first step, column was equilibrated with 8 column volumes (CV) of buffer (start buffer) 
with moderately high salt concentrations. Then, the sample was filtered through 0.2 µm pore size filters 
and applied on the column at a flow rate of 0.5 mL/min. Then, column was washed with 8 CV of washing 
buffer in order to remove all unbound proteins with a flow rate of 1 mL/min. For elution of proteins, an 
elution buffer with a flow rate of 0.5 mL/min was used. During purification, aliquots were collected and 
analyzed by SDS-PAGE (described in section 2.1.5/2.1.5.2). Finally, the column used in the procedure was 
cleaned with 2 CV of EDTA 100 mM, following with 2 CV of water, 2 CV of 6M Guanidinium in PBS solution 
and at least 2 CV of water. To store the column at 4 °C, 2 CV of EtOH 20% was used. 
Table 3. Buffers recipe for HIC purification assays 
 Assay 1 Assay 2 
Samples  Diluted 1:2 with PBS with 5 M NaCl (pH 7.4) 
Start buffer PBS (pH 7.4) PBS with 2.5 M NaCl (pH 7.4) 
Washing buffer 
1. PBS 
2. PBS diluted 1:2 (pH 7.4) 
PBS with 2.5 M NaCl (pH 7.4) 
Elution buffer Tris 50 mM (pH 10) Step gradient elution: 
1. PBS with 2 M NaCl (pH 7.4) 
2. PBS with 1.5 M NaCl (pH 7.4) 
3. PBS with 1 M NaCl (pH 7.4) 
4. PBS with 0.5 M NaCl (pH 7.4) 
5. PBS with 0.25 M NaCl (pH 7.4) 
6. PBS (pH 7.4) 
7. Tris 50 mM (pH 10) 
In the samples with pure frutalin buffer exchange with PD-10 Desalting Column (GE Healthcare) 
was performed. Thus, this column was washed with 10 mL of distilled water, following 25 mL PBS. Then, 
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2.5 mL of the sample was applied on the column and eluted with 3.5 mL PBS. After, samples were stored 
at –20 °C and the column was washed with water and stored in EtOH 20%. 
2.1.3 Production of recombinant frutalin expressed in E. coli 
E. coli Rosseta (DE3) cells, transforming with pETM11 or pETMFh8 encoding His6-frutalin or Fh8-
frutalin [29], respectively, were grown overnight at 37 °C with continuous shaking (180 rpm) in 25 mL LB 
medium (Applichem) supplemented with 30 mg/mL kanamycin (Sigma) and 10 mg/mL chloramphenicol 
(Applichem). The next day, four erlenmeyers were prepared with 250 mL of LB medium supplemented 
with 30 mg/mL kanamycin and 10 mg/mL chloramphenicol to make up 1 L culture. Thus, each of these 
erlenmeyers was inoculated with pre-culture so that the initial 0.02 optical density measured at 600 nm 
(OD600). After inoculation, cell cultures were incubated at 37 °C with continuous shaking (180 rpm) until 
the OD600 reached a value between 0.4 - 0.6. After achieving this OD, the cell culture was maintained 
under stirring but at 18 °C. After 30 minutes, the expression of frutalin was induced by the addition of 
IPTG (Bio-Rad) to a final concentration of 0.2 mM and incubated overnight, at 18 °C with continuous 
shaking (180 rpm). Thereafter, cell pellet was recovered by centrifugation at 4500 rpm, for 15 min, at 4 
°C and supernatant was discarded. Cell pellets were stored at –20 °C. Before and after the induction 
aliquots were recovered for analyze through SDS-PAGE (described in section 2.1.5/2.1.5.1).  
Before the cells being purified (described in section 2.1.4) they were resuspended in 25 mL of 
lysis buffer (50 mM Tris pH 8.0 (JTBacker), 150 mM NaCl (AppliChem), 20 mM Imidazole (Sigma)) with 1 
mM of PMSF (Sigma), 5 µL/mL DNase (Sigma) and 10 µL/mL lysozyme (Sigma). After this, cells were 
sonicated (Branson Sonifier 450, 6 minutes, duty cycle 50%, output 5) and then, the supernatant was 
harvested by centrifugation at 4 °C, 13000 g for 30 min. Supernatant was filtered through 0.45 µm pore 
size filters. Aliquots of total lysates and supernatant were collected for analyses by SDS-PAGE (described in 
section 2.1.5/2.1.5.1). 
2.1.4 Purification of recombinant frutalin expressed in E. coli 
To purify His6-FTL and Fh8-FTL proteins immobilized nickel ion affinity chromatography (IMAC-Ni) 
was performed. Therefore, HisTrap column (GE Healthcare) was used operated with peristaltic pump and 
all the procedure was performed at 4 °C. The column was equilibrated with 4-6 CV with a binding buffer 
(50 mM Tris pH 8.0, 150 mM NaCl, 20 mM Imidazole) with a flow rate of 1 mL/min. Then, the samples 
were applied to the column with a flow rate of 0.5 mL/min (in this stage the proteins with histidines bind to 
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ligands, nickel ions). After this, the column was washed with 5-10 CV of washing buffer (50 mM Tris pH 
8.0, 150 mM NaCl, 40 mM Imidazole) to remove unbound material with a flow rate of 1 mL/min. Then, 
for elution of the target protein an elution buffer with 50 mM Tris pH 8.0, 150 mM NaCl and 300 mM 
Imidazole was used. The purified samples of 5 mL were collected in 15 mL tubes and posteriorly analyzed 
by SDS-PAGE. To clean the column 2 CV of 70% EtOH, following 2 CV of distillate water were applied. 
Then, it was washed with 2 CV of 1M NaOH and at least 2 CV water. To store the column at 4 °C, 2 CV of 
20% EtOH was applied.  
After purification, it was necessary to perform the dialysis. Thus, samples were dialyzed in PBS 
buffer (pH 7.4), overnight, at 4 °C. These proteins were quantified by the Bradford assay with Bio-Rad 
protein reagent (Bio-Rad). Therefore, in 96-well plates, it was loaded 10 µL/well of protein sample with 
200 µL of BioRad Protein reagent diluted 1:5. After 5-10 minutes, the absorbance at 595 nm was 
measured using the Biotech Synergy HT Microplate Reader. Bovine serum albumin (BSA) was used as 
standard. 
2.1.5  SDS-PAGE 
The electrophoresis under denaturing conditions, sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) was based on the Laemmli system [53]. The proteins were analyzed, 
according to this methodology, before, during and after the purification process. This system uses 
polyacrylamide gel with different acrylamide percentages to separate proteins based on the molecular 
weight. In this work, proteins were separated on 12% SDS polyacrylamide gels (SDS-PAGE). The protein 
molecular weight marker used in SDS-PAGE electrophoresis was PageRulerTM Unstained Broad Range 
Protein Ladder (5-250 kDa) from Fermentas. The composition of SDS-polyacrylamide gels is present in 
Table 4.  
Table 4. Composition of SDS polyacrylamide gels 
Reagents Resolving gel (12%) Stacking gel (4%) 
40% Acrilamid/Bis 3 mL 0.5 mL 
0.5 M Tris-HCl, pH 6.8 - 1.25 mL 
1.5 M Tris-HCl, pH 8.8 2.5 mL - 
10% SDS 100 µL 50 µL 
10% APS 50 µL 25 µL 
TEMED 5 µL 2.5 µL 
H2O 4.35 mL 3.17 mL 
Final volume 10 mL 5 mL 
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The samples were treated with the loading sample buffer (0.15 mM Tris-HCl pH 6.8, 10% (w/v) 
SDS, 50% (v/v) Glycerol, 25% (w/v) β-mercaptoethanol and 0.01% (w/v) bromophenol blue) and heated at 
100 °C for 5-10 min. The electrophoresis run was performed at constant voltage 120 V, using the running 
buffer (17.7 mM Tris, 0.25 % (w/v) SDS and 0.2 M Glycine). 
2.1.5.1 Coomassie blue staining method 
After electrophoresis, Coomassie Blue staining method was used to stain gels. Gels were placed in 
distilled water and heated in microwave for 30 seconds, then placed under constant agitation during 3 
minutes. This step is repeated twice with fresh distilled water. Following this, gels were placed in 
Coomassie Blue solution, heated in microwave for 30 seconds and then placed under constant agitation 
during 30 minutes. Finally, Coomassie Blue solution was removed and distilled water was added for 
destaining of the gel. Coomassie Blue solution was prepared dissolving 60-80 mg the Coomassie Brilliant 
Blue G250 in 1 L of distilled water. This solution was stirring with a magnet for 2 to 4 hours. After this, add 
3 mL of concentrated HCL 37% and solution is stored at environment temperature and protected from 
light.  
2.1.5.2 Silver nitrate staining method 
The polyacrylamide gels resulting of SDS-PAGE were stained with silver nitrate to detect proteins 
with lower concentrations. Thus, the gels were washed with 20% ethanol for 10 minutes and washed with 
distilled water for 10 minutes. Then, gels were sensitized with 0.2 g/L sodium thiosulfate for 2-5 minutes. 
After this, the gels were washed twice, for 20 seconds with distilled water. The gels were stained with 2.0 
g/L nitrate prate solution for 30 minutes and then washed with distilled water five times for 10 seconds. To 
develop the color, a solution with 0.07% formaldehyde (37% formaldehyde), 30 g/L potassium carbonate 
anhydrous and 10 mg/L sodium thiosulfate was used. To stop the staining, gels were placed in a solution 
stop (50 g/L tris base and 2.5% acetic acid) and stored in distilled water.  
2.2 Yeast-cell based phenotypic assay 
2.2.1 Plasmids 
The yeast expression vectors pLS89-(TRP1) encoding human wild-type (wt) p53, pRS314-(TRP1) 
encoding human TAp63α, ΔNp63α  and pRS314-(TRP1) encoding human TAp73α with GAL1-10 inducible 
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promoters, were used. Yeast expression vectors pGALL-(LEU2) encoding human procaspase-3, 
procaspase-6 and procaspase-7 under a GAL1-10 promoter were used.  
2.2.2 Yeast strain, transformation and growth conditions 
Saccharomyces cerevisiae strain CG379 (α ade5 his7-2leu2-112 trp1-289α ura3-52 [Kil-O], Yeast 
Genetic Stock Center, University of California, USA) [54] was transformed using the standard lithium 
acetate method [55]. Yeast cells were routinely grown in minimal selective medium with 2% (w/w) glucose 
(Sigma), 0.7 % (w/w) yeast nitrogen base without amino acids (Difco), and all the amino acids required for 
yeast growth (50 µg/mL; Sigma) except tryptophan (for wt p53, TAp63α, ΔNp63α and TAp73α), or except 
leucine (for procaspase-3, -6 and -7). For expression of human proteins, cells were diluted to 0.05 optical 
density (OD600) in selective induction medium, in which glucose was replaced by 2% (w/w) galactose 
(Sigma) and 2% (w/w) raffinose (Sigma). Yeast cells were then incubated at 30 °C, under continuous 
orbital shaking (200 rpm) for approximately 30 h (for wt p53, TAp63α, ΔNp63α and TAp73α) or 42 h (for 
procaspase-3, -6 and -7), corresponding to the time required by control yeast (transformed with the empty 
vectors pLS89, pRS314 or pGALL) to achieve 0.5 OD600. For growth curves experiments of yeast cells 
expressing procaspase-3, procaspase-6 and procaspase-7, the growth of cultures was analyzed by OD600 
up to 50 h. 
2.2.3 Effects of frutalin and compounds on yeast cell growth 
To analyze the effect of frutalin and of the known activator of caspase-3 and -7, PAC-1 [56] , and of 
the known activator of caspase-6, 1541 compound [57], on yeast cell growth, transformed cells were 
incubated in selective induction medium, as described in section 2.2.2, with different concentrations of 
recombinant frutalin expressed in P. pastoris and purified by SEC (0.01 µM, 0.1 µM, 1 µM and 2.5 µM) or 
PBS, or with 10, 25, 50 and 100 µM activator or with DMSO only. The time of incubation was the same 
described in section 2.2.2 according to the protein studied. Yeast cell growth was analyzed after 2 days 
incubation at 30 °C on Sabouraud Dextrose Agar plates (Liofilchem), by counting the number of colony-
forming units (CFU). The percentage of growth was estimated considering as 100 % growth the number of 
CFU obtained with the control yeast (transformed with the empty vector).  
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2.2.4 Western Blot Analysis 
To analyze protein expression in yeast, samples were lysed in CellyticTM Y Cell Lysis Reagent 
(Sigma) in the presence of EDTA-free protease inhibitor cocktail (Boehringer Mannheim). Proteins were 
quantified with Bio-Rad Protein assay (Bio-Rad) and thereafter were electrophoresed on 12% SDS-PAGE 
(described in section 2.1.5). After this, proteins were transferred to a nitrocellulose membrane (GE 
Healthcare). Membranes were blocked with Tris- buffered saline (TBS), pH 7.4 (20 mM Tris-base, 150 mM 
NaCl,) containing 0.05% (v/v) Tween 20 and 5% (w/v) non-fat milk at room temperature for 2 h. For 
detection of procaspase-3, -6 and -7, membranes were probed with anti-procaspase-3 (1:2000, H-277, 
Santa Cruz Biotechnology), anti-procaspase-6 (1:200, Cell Signaling) and anti-procaspase-7 (1:500, Santa 
Cruz Biotechnology) monoclonal antibodies, respectively. For loading control, membranes were stripped 
and incubated with a mouse monoclonal anti-yeast phosphoglycerate kinase (Pgk1p) antibody (1:5000; 
Molecular Probes). Immunoblots were developed by enhanced chemiluminescence.  
2.2.5 Caspase activation analysis 
To evaluate the caspase activation by frutalin the fluorescent caspase inhibitor was used 
(CaspACE, FITC-VAD-FMK In Situ Marker; Promega). Yeast cells growth of control yeast and yeast 
expressing human procaspase-3, -6 and -7 was performed as described in 2.2.3. When the control yeast 
achieved 0.4 OD600, cells were harvested by centrifugation at 4000 rpm for 5 minutes and washed once 
with 500 µL PBS. Then, to 1×106 cells 500 µL PBS was added and collected by centrifugation at 7000 
rpm for 7 minutes. Cells were resuspended in 100 µL PBS-solution containing 12.5 µM FITC-VAD-FMK 
and incubated for 1 h, at 30 °C in the dark (200 rpm). After this, 400 µL PBS was added to the 
suspension and the cells were harvested by centrifugation, washed and resuspended in 500 µL PBS. 
Fluorescence of twenty thousand cells per sample was analyzed using FACSCalibur flow cytometer (BD 
Biosciences), FL1 channel (Excitation/Emission=488/525 nm) and the CellQuest software (BD 
Biosciences). 
2.3 Assays in human tumor cell lines 
2.3.1 Growth conditions of cell culture 
In assays with human tumor cell lines the human colon adenocarcinoma HCT116 cell line 
harboring a wt p53 form (HCT116 p53+/+) and its isogenic derivative, in which p53 has been knocked out 
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(HCT116 p53−/−) was used (kindly provided by Dr. B. Vogelstein, The Johns Hopkins Kimmel Cancer 
Center, Baltimore, MD, USA). Cell lines were routinely cultured in RPMI with ultraglutamine medium 
(Lonza) supplemented with 10% fetal bovine serum (FBS; Gibco) and maintained in a humidified incubator 
at 37 °C containing 5% CO2. When the cells reached the confluence, they were washed with PBS, trypsin 
(Sigma) was added and they were harvested by centrifugation at 12000 g for 5 minutes. After this, cells 
were resuspended in RPMI with ultraglutamine medium.  
2.3.2 Effect of frutalin on the in vitro cell growth of human tumor cells 
The anti-proliferative effect of frutalin was evaluated on a human colon carcinoma cell line with 
(HCT116 p53+/+) and without (HCT116 p53−/−) wt p53 using the protein-binding dye sulforhodamine B 
(Sigma) to assess cell growth [58]. Briefly, cells were plated in 96-well plates at a density of 5 × 103 
cells/well, in RPMI-1640 medium with ultraglutamine I (Lonza) supplemented with 5% fetal bovine serum 
(Gibco), and allowed to adhere overnight in a humidified incubator at 37 °C with 5% CO2 in the air. Cells 
were further incubated for 48 hours with five serial dilutions of recombinant frutalin expressed in P. 
pastoris and in E. coli, starting with the concentration of 1.5 µM or 8.4 µM, respectively. PBS was tested 
with the same volume of the maximum concentration and used as negative control. Following this period, 
adherent cells were fixed in situ with ice cold 10% trichloroacetic acid (TCA; Scharlau) to each well and 
then were incubated for 1 h at 4 °C. Afterward, plates were washed with distilled water and when plates 
were well dried, they were stained with SRB solution (0.4% Sulfurhodamine B in 1% acetic acid) and 
incubated for 30 minutes. Unbound stain was washed with 1% acetic acid and the bound stain was 
solubilized in 10 mM Tris Base. Finally, optical density was measured at 510 nm using a microplate reader 
(Synergy HT; Biotek). The GI50 values (concentration resulting in 50% inhibition of cell growth) were 
determined for frutalin from the plotted results. 
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3.1 Production and purification of recombinant frutalin 
3.1.1 Production and purification of frutalin expressed in Pichia pastoris 
Recombinant frutalin was expressed in P. pastoris as previously described [31]. In order to confirm 
the correct expression of frutalin, the supernatants of methanol-induced cultures were analyzed by SDS-
PAGE and stained with Coomassie. As can be observed in Figure 5 (marked box), frutalin appears as a 
double band with both bands having a molecular weight higher than 15 kDa, partially glycosylated, as 
previously reported [31].  
 
Figure 5. Expression of frutalin in P. pastoris. Analysis of supernatants from methanol-induced cultures in a 12% 
SDS-PAGE stained with Coomassie. Legend: 1, molecular weight standards; 2, frutalin. 
 
After verifying that frutalin was correctly expressed, samples were purified by two different 
purification techniques: size-exclusion chromatography (SEC) and hydrophobic interaction chromatography 
(HIC). SDS-PAGE analysis of the samples after purification by SEC (Figure 6) was performed in order to 
confirm that frutalin was obtained at a high level of purity.   
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Figure 6. Purification of frutalin expressed in P. pastoris. Analyze of frutalin samples obtained from SEC purification 
by Coomassie blue stained 12% SDS-PAGE. Legend: 1, molecular weight standards; 2, frutalin. 
In an attempt to simplify the purification procedure and to decrease its costs, the efficacy of the 
HIC method was evaluated. In order to assess if it was possible to purify frutalin expressed in Pichia 
pastoris from supernatants of methanol-induced cultures by HIC, proteins were separated on 12% SDS-
PAGE and visualized using Coomassie staining (Figure 7A) and silver staining (Figure 7B). For that, two 
independent assays were performed in order to improve the interaction of the frutalin with the hydrophobic 
resin. In the assay 1, some target protein was lost in the flow-through and washing step (lanes 3, 4 and 5 
of Figure 7A). Nevertheless, a large amount of target protein was recovered in elution step (lane 6 and 7 of 
Figure 7A). Despite the loss of protein, frutalin showed a high level of purity. In assay 2, the results were 
more satisfactory than in assay 1 because there was no loss of protein in flow-through and washing step, 
as it can be seen in Figure 7B. In lanes 12-18 of Figure 7B it is possible to observe a high level of 
purification of frutalin. However, this only occurred when the elution buffer was PBS (lanes 12-14 of Figure 
7B) or 50 mM Tris (lanes 15-18 of Figure 7B). With the remaining of the tested elution buffer (lanes 6-11 
of Figure 7B) the elution of frutalin did not occur. For the following studies with human tumor cell lines, the 
samples shown (Figure 7B) in the lanes 12-15 were mixed and corresponding to the concentrate 1 (white 
box marked in silver stained SDS-PAGE gel), and the lanes 16-18 were mixed and corresponding to the 
concentrate 2 (blue box marked in silver stained SDS-PAGE gel) were selected. 
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Figure 7. Analysis of recombinant frutalin samples obtained from HIC purification by Coomassie (assay 1) and 
silver (assay 2) stained 12% SDS-PAGE. (A) Assay 1; Legend: 1, molecular weight standards; 2, frutalin before 
purification; 3, flow-through sample; 4, washing sample; 5, washing sample using PBS (diluted 1:2); 6-7, eluted 
samples; 8, washing column using NaOH; (B) Assay 2; Legend: 1, molecular weight standards; 2, FTL before 
purification; 3, FTL (dilution 1:2 with PBS with 6 M NaCl); 4, flow-through sample; 5, washing sample; 6, eluted 
sample with PBS with 1 M NaCl; 7-8, eluted samples with PBS with 0.5 M NaCl; 9-11, eluted samples with PBS with 
0.25 M NaCl; 12-14, eluted samples with PBS; 15-18, eluted samples with 50 mM Tris (pH 10).  
 
3.1.2 Production and purification of frutalin expressed in E. coli 
Frutalin was expressed in E. coli with two tags: His6 tag and Fh8 tag. A previous study showed that 
the molecular weight of Fh8-FTL is approximately 27 kDa [29]. Thus, SDS-PAGE analysis confirmed that 
Fh8-FTL was expressed correctly and purified with a high level of purity (Figure 8A). In order to confirmed 
that dialysis of eluted samples obtained from IMAC purification occurred as expected, SDS-PAGE analysis 
were performed (Figure 8B).    
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Figure 8. Analysis of Fh8-frutalin samples (A) obtained from nickel affinity purification (IMAC) and (B) after dialysis 
process by Coomassie stained 12% SDS-PAGE. (A) Legend: 1, molecular weight standards; 2, supernatant sample; 
3, flow-through sample; 4-6, washing samples; 7-12, eluted samples. (B) Legend: 1, molecular weight standards; 2-
5, Fh8-frutalin samples.  
 
3.2 Yeast- based assay for the elucidation of the molecular mechanism of 
frutalin  
3.2.1 Implementation of a yeast assay to search for procaspase-3, -6 and -7 
activators  
A previous study showed that recombinant frutalin expressed in Pichia pastoris and purified by 
SEC induced inhibition of cell proliferation in HeLa cells through an apoptotic cell death [33]. Because the 
p53 family members and the executioner caspases are key apoptotic regulators, we evaluated the effect of 
frutalin obtained from P. pastoris and purified by SEC on these proteins. For that, yeast-based assays were 
used. For p53 family proteins (p53, p63, p73, DN) these assays, based on growth analysis were already 
implemented. For the executioner caspases-3, -6 and -7 these assays had to be developed. For that, these 
caspases were expressed in the yeast S. cerevisiae as previously reported [59, 60].  
Expression of procaspase-3, -6 and -7 was confirmed by Western blot analysis using specific 
monoclonal antibodies to each procaspase (Figure 9).  
 
  A B 
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Figure 9. Yeast expression of human procaspase-3 (A), procaspase-6 (B) and procaspase-7 (C) was confirmed by 
Western blot analysis, using anti-procaspase-3, anti-procaspase-6 and anti-procaspase-7 monoclonal antibodies, 
respectively; Pgk1p was used as loading control. Immunoblots were developed by enhanced chemiluminescence. 
In order to analyze the effect of procaspase-3, -6 and -7 in yeast cell growth, growth curves of 
yeast cells expressing human procaspase-3, -6 or -7 and control yeast (pGALL) were obtained. A previous 
study showed that the expression of these human procaspases in yeast did not interfere with the yeast cell 
growth [61]. The growth curves obtained confirms the previously reported data, since, a similar growth 
profile was obtained with control yeast and yeast expressing human procaspase-3, -6 or -7 (Figure 10).  
  
A 
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Figure 10. Growth curves for yeast expressing human procaspase-3 (A), -6 (B) and -7 (C) and control yeast (pGALL) 
assessed by optical density (at 600 nm). Data represent mean ± standard error (S.E.M) of two independent 
experiments; values obtained not statistically different from yeast expressing control empty vector (P >0.05). 
 
To validate these assays for the search of activators, the commercial activators of executioner 
caspases, PAC-1 and compound 1541, were tested. As previously described, PAC-1 is a known activator of 
procaspase-3 and -7 and the compound 1541, a known activator of caspase-6 [56, 57]. As expected, a 
decrease on yeast cell growth to all the procaspases studied, can be observed in response to the standard 
activators. However, for procaspase-6 this growth inhibition was not statistically significant (Figure 11).  
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Figure 11. (A) Effect of PAC-1 on the growth of yeast expressing procaspase-3 (B) Effect of the compound 1541 on 
the growth of yeast expressing procaspase-6 (C) Effect of PAC-1 on the growth of yeast expressing procaspase-7.  
Yeast cells expressing executioner procaspases were incubated in the presence of 10, 25, 50 and 100 µM activator 
compound or DMSO only, for 48 h incubation. For each culture, the percentage of drug-induced growth inhibition 
was estimated considering 100% growth the number of CFU obtained with control yeast (pGALL). Data represent 
mean ± S.E.M (n=3 for procaspase-3; n=2 for procaspase-6 and n=4 for procaspase-7); values significantly different 
from DMSO only (*P<0.05; **P<0.01; ***P<0.001). 
3.2.2 Effect of frutalin on key apoptotic regulators using yeast assays 
Yeast assays were performed to analyze the effect of frutalin expressed in Pichia pastoris and 
purified by SEC in the activity of several apoptotic regulators. These assays are based on the fact that these 
apoptotic regulators induce growth inhibition when expressed and activated in yeast. Yeast cells 
transformed with the empty vector (control) or expressing p53, p63, p73 or DN were incubated with 0.1 
µM or 1 µM frutalin for 30 h. We observed that frutalin did not interfere with the growth of yeast (Figure 
12).  
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Figure 12. Effects of different concentrations of frutalin on the growth of control yeast and yeast expressing p53, 
p63, p73 or DN. For each culture, the percentage of frutalin-induced growth inhibition was estimated considering 
100% growth the number of CFU obtained with PBS only. Data represent mean ± S.E.M of three independent 
experiments; values obtained not statistically different (P> 0.05). 
 
The treatment of yeast cells expressing procaspase-3 with 0.1 and 1 µM of frutalin, markedly 
decreased the growth of cells (Figure 13). Although it was observed a growth inhibition induced by frutalin 
with 0.01 µM, 0.1 µM and 1 µM in yeast cells expressing procaspase-7, this was not statistically 
significant. Additionally, no effect of frutalin was observed on the growth of yeast expressing procaspase-6 
(Figure 13). The results obtained for procaspase-3 suggest that this procaspase may be involved in the 
apoptotic pathway triggered by frutalin.  
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Figure 13. Effects of different concentrations of frutalin on the growth of control yeast (empty vector) and yeast 
expressing procaspase-3, procaspase -6 and procaspase-7, for 42 h treatment. For each culture, the percentage of 
frutalin-induced growth inhibition was estimated considering 100% growth the number of CFU obtained with PBS 
only. Data represent mean ± S.E.M of three independent experiments; values obtained with yeast expressing 
procaspase-3 treated with frutalin 0.1 µM and frutalin 0.1 µM significantly different from PBS (*P< 0.05; ** P<0.01). 
 
Additionally, the effect of frutalin on procaspase-3, -6 and -7 activation was assessed using the 
assay CaspACE FITC–VAD–FMK in yeast. This assay consists in the use of a fluorogenic substrate that 
binds to active caspases. The expression of procaspase-3, -6 and -7 incubated only with the solvent PBS 
already exhibit some caspace activity, which may reflect some basal auto activation (Figure 14). In the 
presence of 0.01 µM, an increase in the activity of 14.94%, 19.05% and 27.67% was observed for yeast 
cells expressing procaspase-3, -6 and -7, respectively. A slight increase of caspases activity was also 
observed in the empty vector, which may reflect the activity of yeast endogenous proteases (Figure 14). In 
this assay, the values obtained showed a higher activation of procaspase-3 and -7 (50.50% and 48.66%, 
respectively) than procaspase-6 (33.55%).  
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Figure 14. Procaspase activity in yeast after treatment with frutalin. Flow cytometric analysis using the FL1 
detection of FITC fluorescence of cells treated with PBS (control) and cells treated with 0.01 µM of frutalin. Data 
represent one experiment with duplicates. Legend: (A) Empty-vector (B) Procaspase-3 (C) Procaspase-6 (D) 
Procaspase-7. 
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3.3 Studies in human tumor cell lines 
In order to confirm the results obtained in yeast, that suggest that the p53 family is not involved in 
the induction of apoptosis by frutalin, the effect of frutalin expressed in Pichia pastoris and purified by SEC 
in human tumor cells of colon adenocarcinoma HCT116 cell line with (HCT116 p53+/+) and without 
(HCT116 p53-/-) wt p53, was evaluated. The effect of frutalin in the inhibition of cell proliferation was 
similar in both HCT116 cell lines analyzed (Figure 15; Table 5). These results confirmed those obtained in 
yeast, indicating that frutalin does not induce cell death by activation of the p53 pathway.   
 
Figure 15. Effect of different concentrations of frutalin on proliferation of HCT116 p53+/+ and HCT116 p53-/- cells 
at 48 h. Data represent mean ± S.E.M of two independent experiments; values obtained are not statistically different 
(P >0.05). 
We also tested the frutalin expressed in P. pastoris and purified by HIC (that resulted in two 
different concentrates as can be observed in Figure 7B). These concentrates were analyzed in human 
tumor cells with wt p53 (HCT116 p53+/+) to evaluate if this purification affects the biological activity of this 
protein. The GI50 value determined for concentrate 1 was higher than that determined for frutalin expressed 
in P. pastoris purified by SEC (frutalin used in the assays of this work). Concerning to the concentrate 2 
none of the concentration tested in tumor cells caused inhibition of cellular proliferation.  
The effect of frutalin expressed by E. Coli (Fh8-FTL) was also evaluated in human tumor cells with 
wt p53 (HCT116 p53+/+) and none of the concentrations tested (0.5 µM, 1.1 µM, 2.1 µM, 4.2 µM and 8.4 
µM) showed inhibition of cell proliferation. 
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Table 5. GI50 of frutalin obtain in HCT116 p53
+/+ and HCT116 p53-/- cells 
Frutalin/ 
Tumor cell lines 
Frutalin 
(Purified by SEC) 
GI50 (µM) ± S.E.M 
Frutalin (purified by HIC) 
GI50 (µM) 
Concentrate 1 Concentrate 2 
HCT116 p53+/+ 0.27 ± 0.037 0.69 High (> 0.55) 
HCT116 p53−/− 0.45 ± 0.083 - - 
Data represent mean ± S.E.M of two independent experiments. 
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Frutalin, a α-D-galactose-binding lectin, was previously shown to have inhibitory activity on the 
proliferation of tumor HeLa cells. In the present work recombinant frutalin was produced and purified from 
Pichia pastoris and Escherichia coli.  
The expression of frutalin in P. pastoris occurred as expected [31]. A double band was observed in 
SDS-PAGE and according to Oliveira et al. [31], the molecular weight obtained on SDS-PAGE confirming 
that the expression of frutalin occurred without excision of linker tetrapeptide, as a single chain protein. 
Moreover, the upper band represents the β-linker-α chain of the glycosylated isoforms wherein the lower 
band corresponds to the β-linker-α chain of the non-glycosylated isoforms [31]. In order to purify frutalin 
expressed in P. pastoris two different purification techniques were performed: size-exclusion 
chromatography and hydrophobic interaction chromatography. According to the previously described [31], 
the purity level of frutalin using SEC was high. The HIC purification by performing two assays with different 
buffers composition was optimized. Concerning to the first assay, some protein was lost in flow-through 
and washing samples. These may be due to the weak interaction between the hydrophobic surface of the 
sample and the hydrophobic ligands of a HIC medium. This suggests that frutalin weakly exposed the 
hydrophobic amino acids residues probably due to lower concentrations of salts in buffers [62, 63]. 
Therefore, in the second assay, the concentration of salts in the sample and in the start buffer was 
increased. Thus, it was expected a stronger exposure of the hydrophobic amino acids residues and, 
consequently, a better interaction between the surface of the sample and the hydrophobic resin [62–64]. 
As expected, it was verified a better interaction since, frutalin was not lost in flow-through and in washing 
samples. Moreover, in this second assay, frutalin showed a high level of purity. 
Concerning the expression of Fh8-frutalin in E. coli, this protein migrated as a single band on SDS-
PAGE. The Fh8-frutalin, show a molecular weight of approximately 27 kDa. Contrary to the frutalin 
expressed in P. pastoris, the frutalin expressed in E. coli is non-glycosylated. This protein showed a high 
level of purity through nickel affinity purification (IMAC). 
Interestingly, the concentrates (1 and 2) of pure frutalin obtained from P. pastoris and purified by 
HIC (second assay) showed different results. The concentrate 1 had a potent anti-proliferative effect 
against tumor cells with wt p53 (HCT116 p53+/+). In opposition, the concentrate 2 had no anti-proliferative 
effect against tumor cells with wt p53 (HCT116 p53+/+). In SDS-PAGE, the lanes correspondents to this 
concentrate do not present the upper band that represents the β-linker-α chain of the glycosylated 
isoforms. However, the intensity of the lower band that corresponds to the β-linker-α chain of the non-
glycosylated isoforms is similar to the concentrate 1. This suggests that the concentrate 2 is non-
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glycosylated. The β-linker-α chain of the glycosylated isoforms is present for concentrate 1 and for frutalin 
purified by SEC. Thus, the absence of anti-proliferative effect for concentrate 2 may be due to the lack of 
glycosylation in the purified frutalin. Glycosylation is very important for the physical and functional 
properties of proteins. Thus, the changes in glycosylation of frutalin may have led to changes in the 
structure and biological activity of this protein [65, 66]. In the purification of frutalin by HIC, the 
concentration of salts in the medium was increased. These salts enhances the changes in the protein 
conformation in order to expose the hydrophobic residues and thus, to interact with hydrophobic ligands of 
the HIC medium [64]. These changes in the structure can lead to the loss of biological activity [64–66]. 
Thus, the decrease of the activity of concentrate 1 (when compared to the frutalin in P. pastoris and 
purified by SEC) may be also due to changes in the frutalin conformation, although in a lower degree than 
that observed with concentrate 2. The absence of anti-proliferative effect of the concentrate 2 it also can be 
due to changes in the frutalin conformation. Concerning to frutalin expressed from E. coli, this had no anti-
proliferative effect in inhibition of cellular proliferation on HCT116 p53+/+ tumor cells. As concentrate 2, 
frutalin expressed in E. coli, is also non-glycosylated, exhibiting a similar effect to this concentrate. Thus, 
the results obtained with concentrate 2 and frutalin from E. coli also suggest that the absence of 
glycosylation contributed to the loss of frutalin biological activity, nevertheless, further experiments should 
be conducted to confirm this hypothesis.  
In a previous study, it was verified that frutalin expressed in P. pastoris and purified by SEC 
induced inhibition of growth cell by apoptosis [33]. Oliveira et al. [33] reported that this frutalin had a 
potent anti-proliferative effect on HeLa cell line (GI50 ≈ 100 µg/mL ≈ 5.85 µM). In the present work, 
frutalin was tested in human colon adenocarcinoma HCT116 cell lines. Similarly, a potent anti-proliferative 
activity was observed for frutalin expressed in P. pastoris and purified by SEC against HCT116 tumor cells.   
As potential drugs in future cancer therapeutics, the understanding of the molecular mechanism 
involved in lectin-induced apoptosis in tumor cells is widely required.  
According to the results obtained in yeast assays, frutalin seems to interfere with the caspase 
pathway, particularly with the procaspase-3. However, the results obtained in the flow cytometric analysis 
also showed the activation of procaspase-6 and -7. This may be due to the small number of assays 
performed in growth assays and in flow cytometric analysis. Thus, further assays should be performed in 
order to confirm if only procaspase-3 is activated. Despite of these, the results suggest that the anti-
proliferative activity of frutalin is mediated through a caspase-dependent pathway. Furthermore, the yeast 
assays indicated that frutalin was not able to activate p53 family proteins. Additionally, studies in human 
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tumor cell with (HCT116 p53+/+) and without (HCT116 p53-/-) wt p53, confirmed that p53 was not involved 
in frutalin-induced apoptosis. These results were consistent with previous data showing that some lectins 
such as Astragalus membranaceus lectin (AML), Concanavalin A (Con A), Polygonatum odoratum lectin 
(POL) and Polygonatum cyrtonema lectin (PCL) induce apoptosis in tumor cells in a caspase-dependent 
pathway. Interestingly, FTL, AML, Con A, POL, and PCL have different carbohydrate-binding specificity [47, 
67–69]. Additionally, lectins such as jacalin and the Cliona varians lectin (CvL), which as frutalin bind 
specifically to galactose, induce apoptosis in a caspase-independent pathway [70, 71]. The carbohydrate-
binding specificity of lectins is very important for their biological activities. However, and according to 
previous data obtained for frutalin and other lectins, it seems that the biological effects of lectins are not 
only dependent on the carbohydrate-binding property [72, 73]. Differences in anti-proliferative activity of 
lectins in tumor cell lines have been reported, confirming that biological effects of lectins not depend only 
of their sugar specificity. A previous report, demonstrate that Galβ1-3Gal-NAcα- binding lectin (jacalin) was 
noncytotoxic inhibitor of proliferation of HT29 colon cancer cells however, was cytotoxic to A431 
epidermoid carcinoma cells [72]. AML induces different responses in growth of K562 and HeLa cell line 
and was more inhibitor of proliferation in the K562 cell line [74].  
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This work aimed to elucidate the molecular mechanism involved in induction of apoptosis by 
frutalin expressed in Pichia pastoris and purified by size-exclusion chromatography. Therefore, using yeast-
based assays the major proteins involved in apoptosis such as caspases executioner and p53 family 
proteins were studied. Moreover, the effect of this frutalin in the proliferation of human tumor cells with 
(HCT116 p53+/+) and without a wt p53 (HCT116 p53-/-) was evaluated. The results obtained suggest that 
frutalin induced apoptosis in a caspase-dependent pathway and that the p53 pathway was not involved in 
frutalin-induced apoptosis.  
 Additionally, we analyzed the effect of frutalin expressed in Escherichia coli on the proliferation of 
HCT116 p53+/+ tumor cells, and showed that this frutalin has no effect in the cell proliferation. Thus, even 
though the production and purification process in E. coli be less time consuming and more straightforward, 
this expression system should not be used for the production and purification of frutalin. Nevertheless, the 
absence of biological activity could be due to the tag presence. Therefore, tag removal should be 
considered and the obtained cleaved frutalin should be evaluated for its effect in the proliferation of human 
tumor cells so that a definitive conclusion can be reached on the use of this bacteria. Frutalin expressed in 
P. pastoris was also purified by hydrophobic interaction chromatography that result in two different 
samples, suggesting that one is partially glycosylated and the other is non-glycosylated. The sample 
partially glycosylated inhibited cell proliferation of HCT116 p53+/+ tumor cells however, less potent than 
frutalin purified by SEC whereas the sample non-glycosylated did not inhibit cell proliferation.  
As future work, it would be interesting to explore the caspase-dependent pathway since this is the 
probable mechanism triggered by frutalin to induce apoptosis. Thus, it would be necessary to confirm the 
activation of procaspase-3, -6 and -7 by frutalin by western blot analysis in human tumor cell lines. Human 
cell lines silenced for these caspases would also validate these proteases as targets of frutalin. Additionally, 
in vitro assays, using recombinant caspases would confirm if these proteases are direct targets of frutalin, 
as suggested by the yeast assays.   
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7.1 Amino-acid sequence of Frutalin expressed in Pichia pastoris 
NQQSGKSQTVIVGPWGAKVSTSSNGKAFDDGAFTGIREINLSYNKETAIGDFQVVYDLNGSPYVGQNHKSFITGFTPV
KISLDFPSEYIMEVSGYTGNVSGYVVVRSLTFKTNKKTYGPYGVTSGTPFNLPIENGLIVGFKGSIGYWLDYFSMYLSL 
7.2 Amino-acid sequence of His-Frutalin expressed in Escherichia coli 
MKHHHHHHPMSDYDIPTTENLYFQGAMGSAEQSGKSQTVIVGPWGAKVSTSSNGKAFDDGAFTGIREINLSYNKET
AIGDFQVIYDLNGRPFVGQSHTSFIKGFTPVKISLDFPSEYIVEVSGHTGKVSGYVVVRSLTFKTNKKTYGPYGVTSGTPF
NLPIENGLVVGFKGSIGYWMDYFSMYLSL 
7.3 Amino-acid sequence of Fh8-Frutalin expressed in Escherichia coli  
MKHHHHHHPMSPSVQEVEKLLHVLDRNGDGKVSAEELKAFADDSKCPLDSNKIKAFIKEHDKNKDGKLDLKELVSI
LSSENLYFQGSMGSAEQSGKSQTVIVGPWGAKVSTSSNGKAFDDGAFTGIREINLSYNKETAIGDFQVIYDLNGRPFVG
QSHTSFIKGFTPVKISLDFPSEYIVEVSGHTGKVSGYVVVRSLTFKTNKKTYGPYGVTSGTPFNLPIENGLVVGFKGSIGY
WMDYFSMYLSL 
 
Legend:    
Beta chain 
Linker tetrapeptide 
Alpha chain 
His6 tag  
Fh8 tag 
 
 
 
 
 
 
 
            
